ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc.
July 31, 2019
· 6 min read